After a morning of frightening scenario's played out by President Bush regarding the possibility of an avian flu pandemic, pharmaceutical giant Roche says it is prepared to tackle the virus along with the U.S. Government.

Roche announces it is prepared to supply its antiviral medication Tamiflu for the Strategic National Stockpile, following President Bush's remarks at the National Institutes of Health Tuesday

Worrisome results from a new pan-European survey of over 250 cancer patients find patients with cancer are failing to receive appropriate treatment for anemia and therefore suffering un-necessarily from the debilitating fatigue it causes.

The survey revealed that over half (58-percent) are not currently receiving EPO therapy (drugs which stimulate the production of oxygen-carrying red blood cells) for their anemia-related fatigue, despite the recommendation of European standards for anemia care

The Food and Drug Administration (FDA) approves a new tablet formulation of Abbott's HIV protease inhibitor Kaletra (lopinavir/ritonavir), which will allow adult patients to take fewer pills with or without food as part of their treatment regimen.

Additionally, there will be no refrigeration requirements for the tablets. These benefits were not available with the old Kaletra capsules. The FDA says the standard daily doses of new Kaletra tablets and capsules provide similar drug levels in the blood

Abbott, a leader in HIV/AIDS research since the early days of the deadly epidemic, announces it has received U.S. Food and Drug Administration (FDA) approval for a new tablet formulation of its HIV protease inhibitor (PI) Kaletra.

The drug will allow adult patients to take fewer pills with or without food as part of their treatment. In contrats to the old drug, there will be no refrigeration requirements for the tablets

GlaxoSmithKline announces that the U.S. Food and Drug Administration (FDA) has approved Arranon (nelarabine) Injection, a chemotherapy agent, for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.

According to GlaxoSmithKline, this use is based on the induction of complete responses. Randomized trials demonstrating increased survival or other clinical benefit have not been conducted